This study examined genetic variants of IL28B rs12979860 as predictors of interferon-based therapy outcomes in people with hepatitis C virus (HCV) in Pakistan. The study found that HCV subgenotype 3a was most prevalent and had higher response rates to therapy than subtype 1a. Carriage of the IL28B rs12979860 CC genotype was associated with higher sustained virological response rates to therapy. In contrast, the IL28B rs8099917 polymorphism was not associated with therapy outcomes. The study concludes that HCV genotype and IL28B rs12979860 can help predict the effectiveness of interferon-plus-ribavirin combination therapy for HCV in Pakistan.